Keywords
Psychedelics
Psychiatric disorders
Depression
Treatment
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the efficacy and safety of the medicinal use of psychedelics and Cannabis in the treatment of symptoms of mental disorders, with emphasis on their potential as alternative therapies in patients with resistance to conventional treatments. Methods: Integrative literature review in PubMed Central (PMC), using the search strategy: ((Cannabis) OR (Psychedelics)) AND (Psychiatric disorders) AND (Therapeutic use). After the initial search, 680 studies were identified and submitted to selection criteria. After applying inclusion and exclusion criteria, 15 articles were selected to compose this study. Results: The impact of psilocybin and MDMA in the relief of symptoms of depression and PTSD was analyzed, as well as the effects of CBD and THC in the management of anxiety and psychotic symptoms, in addition to exploring the main risks and adverse effects associated with the use of these treatments, comparing them with conventional therapies. Final considerations: The use of psychedelic substances, such as psilocybin and MDMA, has shown positive results in clinical practice, increasing the evidence that when used with conventional therapies they can bring many benefits to patients. However, it is currently a subject that is little documented. Therefore, continuous research is needed in order to standardize therapeutic approaches to ensure the minimization of adverse effects.
References
AARONSON ST, et al. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Controlled Trial. JAMA Psychiatry, 2023.
AICHER HD, et al. Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects. Front Psychiatry, 2024; 14:1302559.
BINKOWSKA AA, et al. Cannabidiol usage, efficacy, and side effects: analyzing the impact of health conditions, medications, and cannabis use in a cross-sectional online pilot study. Front. Psychiatry, 2024; 15: e1356009.
DAMMANN I, et al. Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review. Pharmacopsychiatry, 2024."
DAWSON D, et al. The prevalence of cannabis use disorders in people who use medicinal cannabis: A systematic review and meta-analysis. Drug and Alcohol Dependence, 2024; 257: e111263.
ECKERNÄS E, et al. Optimized infusion rates for N,N-dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework. CPT Pharmacometrics Syst Pharmacol, 2023; 12(10):1398-1410.
EVANS J, et al. Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLoS ONE, 2023; 18(10): e0293349."
HAIJEN ECHM, et al. Effects of psychedelic microdosing versus conventional ADHD medication use on emotion regulation, empathy, and ADHD symptoms in adults with severe ADHD symptoms: A naturalistic prospective comparison study. European Psychiatry, 2024; 67(1):e18.
KORKMAZ ND, et al.Psychedelic therapy in depression and substance use disorders. European Journal of Neuroscience, 2024."
MALLICK K, et al. The anxiolytic effects of cannabinoids: A comprehensive review. Pharmacology, Biochemistry and Behavior, 2024; 243: e173828.
MASON NL, et al. Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study. Brain Behav Immun, 2023; 114:299-310.
MÜLLER-VAHL KR. Cannabinoids in the treatment of selected mental illnesses: practical approach and overview of the literature. Pharmacopsychiatry, 2024; 57: 104-114
PEREZ N, et al. Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. European Neuropsychopharmacology 76, 2023; 61–76.
RAISON CL, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial. JAMA , 2023; 330 (9): 843 - 853.
RAJ P, et al. Psychedelic drugs of hallucinogens: exploring their medicinal potencial. Cureus, 2023; 15(11): e48719
SCHOUTEN M, et al. Cannabidiol and brain function: current knowledge and future perspectives. Pharmacology, 2024."
SLOSHOWER J, et al. Psychological fexibility as a mechanism of change in psilocybin‐assisted therapy for major depression: results from an exploratory placebo‐controlled trial. Scientific Reports, 2024.
SZIGETI B, et al. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. Psychological Medicine, 2024.
WOJTAS A. The possible place for psychedelics in pharmacotherapy of mental disorders. Psychedelic Medicine: Therapeutic Applications and Implications for Future Research. Pharmacological Reports (2023).
YADEN DB, et al. IUPHAR-review: The Integration of Classic Psychedelics into Current Substance Use Disorder Treatment Models. Pharmacological Research, 2023.
YERUBANDI A, et al. Acute adverse effects of therapeutic doses of psilocybin: a systematic review and meta-analysis. JAMA Network Open, 2024; 7(4): e245960.